RET C620R - Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene RET
Variant C620R
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions RET C620R lies within the extracellular domain of the Ret protein (PMID: 9230192). C620R results in decreased cell surface Ret expression, but also results in increased Ret and Shc phosphorylation, activation of transcription in a reporter assay, transformation in cell culture (PMID: 9879991, PMID: 9230192), increased Erk phosphorylation and IL3-independent growth in culture (PMID: 36166639).
Associated Drug Resistance
Category Variants Paths

RET mutant RET act mut RET C620R

RET mutant RET C620X RET C620R

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_020975.6
gDNA chr10:g.43113654T>C
cDNA c.1858T>C
Protein p.C620R
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001406743.1 chr10:g.43113654T>C c.1858T>C p.C620R RefSeq GRCh38/hg38
NM_001406759.1 chr10:g.43113654T>C c.1858T>C p.C620R RefSeq GRCh38/hg38
NM_020630 chr10:g.43113654T>C c.1858T>C p.C620R RefSeq GRCh38/hg38
NM_020630.7 chr10:g.43113654T>C c.1858T>C p.C620R RefSeq GRCh38/hg38
NM_001406744.1 chr10:g.43113654T>C c.1858T>C p.C620R RefSeq GRCh38/hg38
NM_001406763.1 chr10:g.43113654T>C c.1858T>C p.C620R RefSeq GRCh38/hg38
NM_020975.5 chr10:g.43113654T>C c.1858T>C p.C620R RefSeq GRCh38/hg38
NM_020630.5 chr10:g.43113654T>C c.1858T>C p.C620R RefSeq GRCh38/hg38
NM_001406760.1 chr10:g.43113654T>C c.1858T>C p.C620R RefSeq GRCh38/hg38
NM_020975.6 chr10:g.43113654T>C c.1858T>C p.C620R RefSeq GRCh38/hg38
NM_020975 chr10:g.43113654T>C c.1858T>C p.C620R RefSeq GRCh38/hg38
NM_001406765.1 chr10:g.43113654T>C c.1858T>C p.C620R RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RET C620R medullary thyroid carcinoma predicted - sensitive Everolimus Case Reports/Case Series Actionable In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease of 116 weeks in a MEN2A patient with medullary thyroid cancer harboring a RET C620R mutation (PMID: 26294908; NCT01118065). 26294908
RET C620R Advanced Solid Tumor sensitive Selpercatinib Preclinical - Cell culture Actionable In a preclinical study, Retevmo (selpercatinib) inhibited viability in transformed cells expressing RET C620R in culture (PMID: 36166639). 36166639
RET C620R Advanced Solid Tumor sensitive Pralsetinib Preclinical - Cell culture Actionable In a preclinical study, Gavreto (pralsetinib) inhibited viability in transformed cells expressing RET C620R in culture (PMID: 36166639). 36166639